ASNC is the premier source for education and quality in the rapidly expanding area of cardiac amyloidosis.
Through its initiatives and partnerships, ASNC is supporting a collaborative approach to awareness, early diagnosis, and effective treatments that will save lives and improve the quality of life for patients with CA. Access the latest educational resources and activities including our new app and share with your colleagues!
ASNC has developed Cardiac Amyloidosis OnDemand, a 3-module CME accredited program so you can learn the A-Z's of cardiac amyloidosis to diagnose and treat patients in today's multimodality imaging environment.
This curriculum features content from ASNC's array of amyloid programs curated to meet your needs. Each module contains two video presentations from leading experts discussing the diagnosis, treatment, and management of patients with cardiac amyloidosis.
Earn up to 2.25 CME credits.
MEMBERS GET FREE ACCESS!
ASNC Issues Statement on How to Use HMDP in Cardiac Amyloidosis Imaging
Shortages of pyrophosphate (PYP), the radiopharmaceutical most commonly used in the U.S. for noninvasive diagnosis of transthyretin (ATTR) cardiac amyloidosis, should not delay imaging in at-risk patients. Instead, ASNC is guiding imagers to use 99mtechnetium (99mTc)-hydroxymethylene diphosphonate (HMDP or HDP) to ensure patients continue receiving prompt evaluation of, and treatment for, cardiac amyloidosis.
Download our new 11"x17" flowchart designed to guide your clinical assessment of cardiac amyloidosis.
Download our Transthyretin Cardiac Amyloidosis: Frequently Asked Questions guide.
Download the Clinical and Quality Resources App
Hover over the QR code with your camera to download
ASNC is uniquely qualified to provide education, information and advocacy that ensures appropriate referrals for Tc-99m PYP imaging; supports high-quality testing, interpretation and reporting of Tc-99m PYP imaging by imagers; and encourages fair reimbursement of Tc-99m PYP services and approval of CA treatment agents.